Insider Trading March 12, 2026

Rapid Micro Biosystems COO Sells $41K in Stock as Company Posts Mixed Q4 Results

John J. Addington Wilson disposed of 9,603 shares to meet tax liabilities; Rapid Micro Biosystems reported revenue beat but a wider-than-expected loss for Q4 2025

By Priya Menon RPID
Rapid Micro Biosystems COO Sells $41K in Stock as Company Posts Mixed Q4 Results
RPID

Rapid Micro Biosystems Chief Operating Officer John J. Addington Wilson sold 9,603 Class A shares on March 11, 2026, in a transaction totaling $41,466 to cover tax obligations tied to restricted stock vesting. The sale was disclosed on a Form 4 filing with the SEC. The company recently reported Q4 2025 revenue of $11.3 million, beating analyst expectations, while reporting a net loss per share that exceeded estimates.

Key Points

  • Rapid Micro Biosystems COO John J. Addington Wilson sold 9,603 Class A shares on March 11, 2026, for $4.3181 per share, totaling $41,466.
  • The sale was executed to cover tax obligations associated with the vesting of restricted stock units; after the sale Wilson directly owns 316,762 shares.
  • Rapid Micro Biosystems reported Q4 2025 revenue of $11.3 million, beating the $9.83 million analyst estimate and rising 37% year-over-year, while reporting a net loss per share of $0.28 versus an expected $0.225.

John J. Addington Wilson, the Chief Operating Officer of Rapid Micro Biosystems (NASDAQ: RPID), executed a sale of 9,603 shares of Class A Common Stock on March 11, 2026, a transaction that appears in a Form 4 filing with the Securities and Exchange Commission.

The shares were disposed of at a price of $4.3181 per share, producing a total transaction value of $41,466. According to the filing, the sale was made to satisfy tax obligations arising from the vesting of restricted stock units.

Following the transaction, Wilson is reported to directly own 316,762 shares of the company. The timing of the sale aligns with recent share-price movement: Rapid Micro Biosystems shares have fallen roughly 17 percent over the past week, trading at approximately $3.42 at the time of the disclosure.


Separately, Rapid Micro Biosystems released fourth-quarter 2025 financial results that showed mixed outcomes. The company reported revenue of $11.3 million for the quarter, outperforming analyst expectations of $9.83 million and representing a 37 percent increase compared with the prior year.

Despite the top-line beat, the company reported a net loss per share of $0.28, which was larger than analysts had anticipated at $0.225 per share. The earnings call accompanying the results underscored financial challenges, as evidenced by the greater-than-expected loss. Company management and analysts noted that while revenue growth was strong, the earnings outcome did not meet investor expectations.

These developments - the insider sale and the quarterly results - provide data points investors can use when assessing Rapid Micro Biosystems' near-term financial position. The Form 4 filing and the quarterly report together document recent executive transactions and operational results without providing new guidance on future performance.


Summary

Rapid Micro Biosystems' COO sold 9,603 shares for $41,466 on March 11, 2026 to cover tax liabilities tied to RSU vesting. The company reported Q4 2025 revenue that exceeded analyst estimates but posted a wider-than-expected net loss per share.

Risks

  • Share-price volatility - the company’s stock declined about 17% over the prior week and traded near $3.42, a factor relevant to equity investors and the capital markets.
  • Profitability challenges - the wider-than-expected net loss per share highlights near-term financial strain that could affect investor sentiment in the healthcare and biotech sectors.
  • Analyst-expectation divergence - the mismatch between revenue beats and earnings misses creates uncertainty for future evaluations by analysts and market participants in medical technology and related markets.

More from Insider Trading

Doximity interim PFO sells Class A stock worth $58,833; firm posts beat amid mixed analyst views Mar 12, 2026 Doximity Interim Finance Chief Sells $63,622 in Stock; Converts and Exercises Additional Shares Mar 12, 2026 AdaptHealth insider increases stake with $19.9 million stock purchases Mar 12, 2026 Loar Holdings CEO's Family Trust Buys $2.97M in Company Stock Over Three Days Mar 12, 2026 Baskett Forest Increases Stake in Korro Bio with $2.3 Million Purchase Mar 12, 2026